Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis

• Type: Another Publication in an International Scientific Journal
• Date: 2018

Authors

Fachi, MM (Author) Other; Tonin, FS (Author) Other; Leonart, LP (Author) Other; Aguiar, KS (Author) Other; Lenzi, L (Author) Other; Figueiredo, BC (Author) Other; Fernandez Llimos, F (Author) Other; Pontarolo, R (Author) Other

Journal

Title: European Journal of Cancer

Vol. 104

Pages: 9-20

ISSN: 0959-8049

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 22 Citations

Scopus - 26 Citations

Other information

Authenticus ID: P-00P-PT3

DOI: 10.1016/j.ejca.2018.08.016

Abstract (EN): Background: The pharmacotherapy of chronic myeloid leukaemia (CML) is mainly based on tyrosine kinase inhibitors (TKIs). The aim of this study was to compare the efficacy and safety of all TKIs in CML patients. Methods: We conducted a systematic review with network meta-analysis (NMA) of randomised controlled trials (RCTs), including imatinib, nilotinib, dasatinib, bosutinib, radotinib and ponatinib. Searches were performed in PubMed, Scopus, Web of Science and SciELo (March 2018). The NMAs were built for six outcomes at 12 months: complete cytogenetic response (CCyR), major cytogenetic response (MCyR), deep molecular response, major molecular response (MMR), complete haematologic response and incidence of serious adverse events. We conducted rank order and surface under the cumulative ranking curve (SUCRA) analyses. Results: Thirteen RCTs were included (n = 5079 patients). Statistical differences were observed for some comparisons in all outcomes. Imatinib 400 mg was considered the safest drug (SUCRA values of 10.3%) but presented low efficacy. Overall, nilotinib 600 mg was superior to the other TKI in efficacy (SUCRA values of 61.1% for CCyR, 81.0% for MMR, 90.0% for MCyR); however, no data on its safety profile at 12 months were reported. Interpretation: Our results suggest that nilotinib should be upgraded to first-line therapy for CML, although further cost-effectiveness analyses, including the new TKI (i.e., ponatinib, radotinib), are needed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12